» Articles » PMID: 34552618

Establishment of an Endocytosis-Related Prognostic Signature for Patients With Low-Grade Glioma

Overview
Journal Front Genet
Date 2021 Sep 23
PMID 34552618
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Low-grade glioma (LGG) is a heterogeneous tumor that might develop into high-grade malignant glioma, which markedly reduces patient survival time. Endocytosis is a cellular process responsible for the internalization of cell surface proteins or external materials into the cytosol. Dysregulated endocytic pathways have been linked to all steps of oncogenesis, from initial transformation to late invasion and metastasis. However, endocytosis-related gene (ERG) signatures have not been used to study the correlations between endocytosis and prognosis in cancer. Therefore, it is essential to develop a prognostic model for LGG based on the expression profiles of ERGs.

Methods: The Cancer Genome Atlas and the Genotype-Tissue Expression database were used to identify differentially expressed ERGs in LGG patients. Gene ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene set enrichment analysis methodologies were adopted for functional analysis. A protein-protein interaction (PPI) network was constructed and hub genes were identified based on the Search Tool for the Retrieval of Interacting Proteins database. Univariate and multivariate Cox regression analyses were used to develop an ERG signature to predict the overall survival (OS) of LGG patients. Finally, the association between the ERG signature and gene mutation status was further analyzed.

Results: Sixty-two ERGs showed distinct mRNA expression patterns between normal brain tissues and LGG tissues. Functional analysis indicated that these ERGs were strikingly enriched in endosomal trafficking pathways. The PPI network indicated that EGFR was the most central protein. We then built a 29-gene signature, dividing patients into high-risk and low-risk groups with significantly different OS times. The prognostic performance of the 29-gene signature was validated in another LGG cohort. Additionally, we found that the mutation scores calculated based on the , , , and mutation status were significantly correlated with the endocytosis-related prognostic signature. Finally, a clinical nomogram with a concordance index of 0.881 predicted the survival probability of LGG patients by integrating clinicopathologic features and ERG signatures.

Conclusion: Our ERG-based prediction models could serve as an independent prognostic tool to accurately predict the outcomes of LGG.

Citing Articles

A systematic computational analysis of the endosomal recycling pathway in glioblastoma.

Joyce L, Lindsay A Biochem Biophys Rep. 2024; 38:101700.

PMID: 38638676 PMC: 11024495. DOI: 10.1016/j.bbrep.2024.101700.


Establishment and Validation of a Four-stress Granule-related Gene Signature in Hepatocellular Carcinoma.

Li M, Fan X, Zhao J, Wang D J Clin Transl Hepatol. 2024; 12(1):1-14.

PMID: 38250470 PMC: 10794267. DOI: 10.14218/JCTH.2023.00019.


Endocytosis in cancer and cancer therapy.

Banushi B, Joseph S, Lum B, Lee J, Simpson F Nat Rev Cancer. 2023; 23(7):450-473.

PMID: 37217781 DOI: 10.1038/s41568-023-00574-6.


Signaling pathways in brain tumors and therapeutic interventions.

Li S, Wang C, Chen J, Lan Y, Zhang W, Kang Z Signal Transduct Target Ther. 2023; 8(1):8.

PMID: 36596785 PMC: 9810702. DOI: 10.1038/s41392-022-01260-z.


P-Rex1 Signaling Hub in Lower Grade Glioma Patients, Found by Data Mining, Correlates With Reduced Survival and Augmented Immune Tumor Microenvironment.

Beltran-Navarro Y, Reyes-Cruz G, Vazquez-Prado J Front Oncol. 2022; 12:922025.

PMID: 35875157 PMC: 9300953. DOI: 10.3389/fonc.2022.922025.

References
1.
Taguchi T, Misaki R . Palmitoylation pilots ras to recycling endosomes. Small GTPases. 2011; 2(2):82-84. PMC: 3136908. DOI: 10.4161/sgtp.2.2.15245. View

2.
Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

3.
Morimoto S, Nishimura N, Terai T, Manabe S, Yamamoto Y, Shinahara W . Rab13 mediates the continuous endocytic recycling of occludin to the cell surface. J Biol Chem. 2004; 280(3):2220-8. DOI: 10.1074/jbc.M406906200. View

4.
Juchum M, Gunther M, Laufer S . Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Drug Resist Updat. 2015; 20:12-28. DOI: 10.1016/j.drup.2015.05.002. View

5.
Jia Q, Wang J, He N, He J, Zhu B . Titin mutation associated with responsiveness to checkpoint blockades in solid tumors. JCI Insight. 2019; 4(10). PMC: 6542599. DOI: 10.1172/jci.insight.127901. View